Here's the fullview of this news release about SLO17 Topical Gel. Thanks for the information.


"Quest PharmaTech Initiates a Fifty Patient Pivotal Clinical Trial for Cosmetic Hair Removal Applications
Trading Symbol: QPT: TSX Venture Exchange

- SL017 Receives Health Canada Clearance -

EDMONTON, Jan. 9 /CNW/ - Quest PharmaTech Inc. ("Quest" or the "Company")
is pleased to announce that it has received clearance from the Therapeutic
Products Directorate of Health Canada to initiate a Fifty Patient clinical
trial to investigate the appropriate light dose to be used with the topical
gel for cosmetic hair removal applications of its lead photodynamic therapy
(PDT) compound SL017. The Principal Investigator for the trial is Dr. Robert
Bissonnette, M.D., President of Innovaderm Research in Montreal. Innovaderm
has already received necessary ethics committee approval to recruit patients
for this trial. The trial is anticipated to be completed in six months.
Quest has already completed a Phase I study for the assessment of
histological localization of SL017 Topical Gel in hair follicles. The Phase I
study results demonstrated that the product is well tolerated with
preferential localization of the drug in hair follicles.


Note***The current trial is designed to study the combination of SL017 Topical Gel with Intense Pulse
Light for hair removal.***


Permanent removal of unwanted hair remains a considerable therapeutic
challenge. Over the past few years, new technologies have emerged for hair
removal. One of them is photo-epilation. This technology is based on laser and
other light sources emitting in red and/or near-infrared wavelength regions.


NOTE*****Although these techniques have been shown to induce permanent hair reduction,
a series of 4-8 sessions, and sometimes more, are required. In addition, this
will only achieve a 75%-85% permanent hair reduction and the use of another
technique, such as electrolysis is often necessary after the laser or Intense
Pulse Light treatment. Another main limitation of light based hair removal is
the inability to reduce the number of blond, red or white hairs.*****

The use of SL017 that localizes in the hair follicle has the potential to overcome these
limitations and enhance the effectiveness of photo-epilation.
Quest's strategy is to market SL017 to Asian and Canadian consumers as an
"aid for hair removal with an approved light based depilatory system". The
Company is in the process of registering SL017 as a cosmetic ingredient with
International Nomenclature of Cosmetic Ingredient. The Company is also
developing an 'over the counter' light delivery system that will expand the
market potential of SL017. In September 2006, Quest reached an agreement with
KMH Co., Ltd. of Korea to distribute SL017 in Asia for cosmetic hair removal.
The Company is seeking strategic partners for SL017 for North America and
Europe.

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT),
Alberta-based drug development company committed to the development and
commercialization of new pharmaceutical products. It is developing a series of
products for the treatment of cancer and dermatological conditions based on
its unique photodynamic and sonodynamic therapy platform.

Note: ****Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."

%SEDAR: 00008400E


For further information: Dr. Madi R. Madiyalakan, CEO, Tel.: (780)
448-1400 (Ext. 204), madi@questpharmatech.com, Web site:
www.questpharmatech.com

hey say that it will be marketed to consumers from canada and Asia. Is it because Canada doesn't require to have III phase trials to market the product unlike United States?

That's definitely some good news. In 6 months we should have a good idea how well this treatment will work.

I emailed them asking how long do they think it would take to market this product to consumers. They said they are targeting 2008. WOW:) If everything goes as planned we can have superior hair removal in a year or two. Fingers crossed!!

thanks for that hairyb.

Here is a small write up on Quest's phase I clinical trial for hair removal. It doesn't give any results but it "compares" their method with laser.

http://www.questpharmatech.com/sl017.htm

Anybody know for sure if the Quest clinical trials have started yet? They said six months right? Anyone know when their results will be stated?

Yes Eddy,

Trials have started. They will conclude by June they said. I tried writing them before trials started and they replied when the second trial would begin and end. I wrote them again but never got another response.

A little bit of new information that shows progress of the SL017 compound from Quest.

http://micro.newswire.ca/release.cgi?rkey=1503056628&view=43406-0&Start=0

Quest PharmaTech Closes `Over-Subscribed' Private Placement
Trading Symbol: QPT: TSX Venture Exchange

- $960,000 in equity financing

EDMONTON, March 5 /CNW/ - Quest PharmaTech Inc. ("Quest" or the "Company") announces that further to its January 24, 2007 news release, and subject to TSX Venture Exchange approval, the Company has closed its non-brokered private placement with the sale of 9,600,000 units ("Units") for gross proceeds of $960,000, including $165,000 raised from insiders of the
Company. Originally, the Company expected to raise $800,000 (including $300,000 from our strategic partner KMH Co., Ltd.) through the sale of 8,000,000 units. However, due to an increase in demand, the Company has increased the size of the private placement. The Company still anticipates receiving an additional $1,300,000 of equity investment from KMH Co. Ltd. upon
reaching certain milestones related to commercialization of SL017 for hair removal applications.
The Company is pleased to announce that it has already achieved one such milestone by successfully registering SL017 as a cosmetic ingredient with the International Nomenclature of Cosmetic Ingredient as well as with the Cosmetic, Toiletry and Fragrance Association. In addition, the Company has registered SL017 in Canada as a new substance to allow import/export of the
chemical.
The Units under the current private placement were sold at a price of $0.10 per Unit. Each Unit consisted of one common share of the Corporation ("Common Share") and one-half of one non-transferable share purchase warrant ("Warrant"). Each whole Warrant entitles the holder to acquire one additional Common Share at a price of $0.20. The warrants will expire 12 months from the date of issue.
The Units were issued to qualified purchasers in Alberta, British Columbia and outside of Canada in reliance upon exemptions from the applicable registration and prospectus requirements of securities legislation. The Common Shares and Warrants comprising the Units and the Common Shares issued upon
exercise of the Warrants are subject to a restricted period which expires 4 months from the date of issuance of the Units. The funds raised will be used for general corporate purposes over the coming 6 months including completion of the ongoing 50 patient hair removal clinical trial in Canada.
"I am very pleased with the overwhelming response we received for this round of equity financing. In addition, I am excited to welcome new investors into the Company including a few from Europe" said Dr. Madi R. Madiyalakan, CEO of the Company.

About Quest PharmaTech Inc.

The Corporation is a publicly traded (TSX Venture Exchange: QPT), Alberta-based drug development company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on
its unique photodynamic and sonodynamic therapy platform.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

"TSX Venture Exchange has neither approved nor disapproved of the information contained herein."

%SEDAR: 00008400E

Can you explain what SL017 means? Is that the permanent hair removal topical?

Can you break all this down into 5th grade terms? It sounds like they are coming up with some venture capital to move ahead on these ideas? Yes? No?